Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Pilot Clinical Trial of Lurbinectedin (Zepzelca™ PM01183) in Patients With Gastrointestinal Malignancies With DNA Repair Mutations

NCT05229588 is registered in ClinicalTrials.gov with HonorHealth Research Institute as lead sponsor.

NCT NCT05229588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05229588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Pilot Clinical Trial of Lurbinectedin (Zepzelca™ PM01183) in Patients With Gastrointestinal Malignancies With DNA Repair Mutations
Lead sponsor
HonorHealth Research Institute
Phase
Phase 2
Overall status
Completed
Start date
June 14, 2022
Completion date
August 4, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal malignancies